Mechanisms of Antibiotic Resistance and Developments in Therapeutic Strategies to Combat Klebsiella pneumoniae Infection
Yanping Li,Suresh Kumar,Lihu Zhang
DOI: https://doi.org/10.2147/idr.s453025
2024-03-19
Infection and Drug Resistance
Abstract:Yanping Li, 1, 2 Suresh Kumar, 3 Lihu Zhang 1 1 Pharmacy Department, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, People's Republic of China; 2 Post Graduate Centre, Management and Science University, Shah Alam, Malaysia; 3 Department of Diagnostic and Allied Health Science, Faculty of Health and Life Sciences, Management and Science University, Shah Alam, Malaysia Correspondence: Lihu Zhang; Suresh Kumar, Email ; Infections with drug-resistant bacteria have become one of the greatest public health challenges, and K. pneumoniae is among the top six drug-resistant bacteria. K. pneumoniae often causes nosocomial infections, leading to illnesses such as pneumonia, liver abscesses, soft tissue infections, urinary tract infections, bacteremia, and in some cases death. As the pathogen continues to evolve and its multidrug resistance increases, K. pneumoniae poses a direct threat to humans. Drug resistance in K. pneumoniae may occur due to the formation of biofilms, efflux pumps, and the production of β-lactamases. In many cases, resistance is further enhanced by enzymatic modification and loss of porins. Drug resistance to K. pneumoniae has led to a decline in the effectiveness of conventional therapies against this pathogen. Therefore, there is an urgent need to accelerate the development of new antibiotics and explore new therapeutic approaches such as antimicrobial peptides, phages, traditional Chinese medicine, immunotherapy, Antimicrobial nanoparticle technology, antisense oligonucleotides and gene editing technologies. In this review, we discuss the mechanisms of drug resistance in K. pneumoniae and compare several new potential therapeutic strategies to overcome drug resistance in the treatment of K. pneumoniae infections. Keywords: Klebsiella pneumoniae , antibiotic resistance mechanisms, therapeutic strategies Klebsiella pneumoniae (K. pneumoniae) is a gram-negative bacterium found primarily in the respiratory tract and intestines of humans, often causes nosocomial infections, leading to illnesses such as pneumonia, liver abscesses, soft tissue infections, urinary tract infections, bacteremia, and in some cases death. 1–3 Due to the irrational use of some antibiotics and the evolution of bacteria, drug-resistant bacterial infections have become one of the greatest public health challenges. In 2019, more than 1.2 million people died from drug-resistant bacterial infections, exceeding the number of deaths caused by HIV/AIDS or malaria. K. pneumoniae is also one of the six major drug-resistant bacteria. 2,3 The World Health Organization recognizes that extended-spectrum β-lactam (ESBL) and carbapenem-resistant K. pneumoniae (CRKP) pose significant public health threats. Currently, CRKP has been reported in Greece, China, Eastern Europe, Argentina and the Philippines. 4 In Europe alone, this strain type is reported to cause over 90,000 infections and over 7000 deaths annually, accounting for 25% of deaths caused by multidrug-resistant (MDR) bacterial infections. 5 The global resistance rate of MDR bacteria is increasing. The detection rate of CRKP is increasing from less than 0.1% to 24.6% in the United States. The resistance rate of K. pneumoniae isolates in Greek hospital wards reaches 52.4%. The China Antibiotic Surveillance Network (CHINET) shows that the resistance rate of K. pneumoniae to carbapenems increased from 2.4% to 32.8%. 6 This increased resistance has severely limited therapeutic options and makes combating infections with multidrug-resistant (MDR) and extremely drug-resistant (XDR) K. pneumoniae a global challenge. 7–9 The search for innovative therapeutic strategies has become particularly urgent. K. pneumoniae poses an immediate threat to humans and is becoming increasingly multi-resistant as the pathogen continues to develop. However, there are no approved treatments or vaccines other than traditional antibiotics, and there is an urgent need to accelerate the development of new antibiotics and explore new therapeutic approaches. In recent years, the number of published manuscripts on novel therapeutic strategies for K. pneumoniae has increased dramatically. In this review, we present the mechanisms of antibiotic resistance in K. pneumoniae and compare several new potential therapeutic strategies to overcome resistance in the treatment of K. pneumoniae infections. Antibiotic resistance in K. pneumoniae is achieved through multiple mechanisms that enhance antimicrobial resistance through biofilm formation while also undergoing frequent horizontal transfer of antibiotic resi -Abstract Truncated-
pharmacology & pharmacy,infectious diseases